[go: up one dir, main page]

CO6321270A2 - Nuevas posibilidades de lucha contra la giardiasis - Google Patents

Nuevas posibilidades de lucha contra la giardiasis

Info

Publication number
CO6321270A2
CO6321270A2 CO10162857A CO10162857A CO6321270A2 CO 6321270 A2 CO6321270 A2 CO 6321270A2 CO 10162857 A CO10162857 A CO 10162857A CO 10162857 A CO10162857 A CO 10162857A CO 6321270 A2 CO6321270 A2 CO 6321270A2
Authority
CO
Colombia
Prior art keywords
fight against
new possibilities
giardiasis
nifurtimox
against giardiasis
Prior art date
Application number
CO10162857A
Other languages
English (en)
Inventor
Gisela Greif
Achim Harder
Thomas Bach
Gabriele Petry
Eva Maria Kruedewagen
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CO6321270A2 publication Critical patent/CO6321270A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

1.- Uso de nifurtimox para la preparación de medicamentos para el tratamiento de enfermedades causadas por giardias.2.- Uso según la reivindicación 2 para el tratamiento de enfermedades causadas por Giardia lamblia.3.- Agente que contiene nifurtimox y un antihelmíntico.4.- Agente que contiene nifurtimox y un ciclooctadepsipéptido antihelmíntico.
CO10162857A 2008-07-02 2010-12-27 Nuevas posibilidades de lucha contra la giardiasis CO6321270A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008031284A DE102008031284A1 (de) 2008-07-02 2008-07-02 Neue Bekämpfungsmöglichkeit der Giardiose

Publications (1)

Publication Number Publication Date
CO6321270A2 true CO6321270A2 (es) 2011-09-20

Family

ID=41077987

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10162857A CO6321270A2 (es) 2008-07-02 2010-12-27 Nuevas posibilidades de lucha contra la giardiasis

Country Status (30)

Country Link
US (1) US8440612B2 (es)
EP (1) EP2310018B1 (es)
JP (1) JP5627579B2 (es)
KR (1) KR101720805B1 (es)
CN (1) CN102083441B (es)
AR (1) AR072425A1 (es)
AU (1) AU2009266125B2 (es)
BR (1) BRPI0913889B1 (es)
CA (1) CA2729730C (es)
CL (2) CL2010001577A1 (es)
CO (1) CO6321270A2 (es)
CR (1) CR20110022A (es)
DE (1) DE102008031284A1 (es)
DK (1) DK2310018T3 (es)
DO (1) DOP2010000405A (es)
EC (1) ECSP10010720A (es)
ES (1) ES2444581T3 (es)
HK (1) HK1158113A1 (es)
IL (1) IL209698A (es)
MX (1) MX2010014446A (es)
MY (1) MY157007A (es)
NI (1) NI201100008A (es)
NZ (1) NZ590276A (es)
PE (1) PE20110283A1 (es)
PL (1) PL2310018T3 (es)
RU (1) RU2538713C9 (es)
SV (1) SV2011003785A (es)
UA (1) UA103328C2 (es)
WO (1) WO2010000399A1 (es)
ZA (1) ZA201009225B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173898B2 (en) * 2010-10-12 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating giardiasis
US10081656B2 (en) 2015-05-20 2018-09-25 Merial, Inc. Anthelmintic depsipeptide compounds
NZ743913A (en) 2015-12-28 2019-04-26 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic depsipeptide compounds
CN110167921A (zh) 2016-11-16 2019-08-23 勃林格殷格翰动物保健美国公司 驱蠕虫缩肽化合物
EP3750527A1 (en) * 2019-06-13 2020-12-16 Bayer AG Stable tablet formulation of nifurtimox and process for producing the same
CN114377018B (zh) * 2020-10-21 2024-02-06 中国医学科学院药物研究所 硝呋莫司在制备抗流感病毒药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170957B (de) * 1962-11-23 1964-05-27 Bayer Ag Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten
JPH081908B2 (ja) * 1987-07-22 1996-01-10 三菱電機株式会社 超格子半導体素子
NO176766C (no) * 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
DE122005000058I1 (de) * 1992-03-17 2006-04-27 Astellas Pharma Inc Depsipeptide, Herstellung und Anwendung
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
KR100309091B1 (ko) 1993-02-19 2001-12-28 이치로 키타사토 환상 데프시펩티드 pf 1022의 유도체
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
JP3263947B2 (ja) 1993-09-06 2002-03-11 藤沢薬品工業株式会社 環状デプシペプチド化合物
DE4401389A1 (de) 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
RU2074038C1 (ru) * 1994-06-16 1997-02-27 Товарищество с ограниченной ответственностью Предприятие "ТЕПАРК" Способ изготовления полых металлических емкостей
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
WO1997002256A1 (fr) * 1995-06-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. Derive depsipeptidique, son procede de production et son nouvel intermediaire
CZ295705B6 (cs) 1995-09-22 2005-10-12 Bayer Aktiengesellschaft Cyklodepsipeptidové deriváty sloučeniny PF1022 a farmaceutický prostředek s jejich obsahem
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5874630A (en) * 1998-01-06 1999-02-23 Occidental Chemical Corporation Synthesis of mercaptans from alcohols
US6133228A (en) * 1998-05-28 2000-10-17 Firmenich Sa Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters
DE19828047A1 (de) * 1998-06-24 1999-12-30 Bayer Ag Substituierte Cyclooctadepsipeptide
JP2008519844A (ja) * 2004-11-12 2008-06-12 セルジーン・コーポレーション 寄生虫性疾患の治療及び管理のために免疫調節化合物を使用する方法及び組成物
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel

Also Published As

Publication number Publication date
CR20110022A (es) 2011-05-10
DE102008031284A1 (de) 2010-01-07
PE20110283A1 (es) 2011-05-07
RU2011103475A (ru) 2012-08-10
JP5627579B2 (ja) 2014-11-19
US8440612B2 (en) 2013-05-14
CN102083441B (zh) 2013-07-24
ECSP10010720A (es) 2011-01-31
SV2011003785A (es) 2011-05-20
BRPI0913889A2 (pt) 2015-10-27
RU2538713C9 (ru) 2015-08-20
JP2011526265A (ja) 2011-10-06
CA2729730A1 (en) 2010-01-07
IL209698A (en) 2016-03-31
HK1158113A1 (en) 2012-07-13
EP2310018A1 (de) 2011-04-20
CA2729730C (en) 2016-03-22
DOP2010000405A (es) 2011-01-15
RU2538713C2 (ru) 2015-01-10
DK2310018T3 (da) 2014-03-24
MY157007A (en) 2016-04-15
KR101720805B1 (ko) 2017-03-28
UA103328C2 (uk) 2013-10-10
US20110105388A1 (en) 2011-05-05
EP2310018B1 (de) 2013-12-18
ZA201009225B (en) 2012-03-28
AR072425A1 (es) 2010-08-25
MX2010014446A (es) 2011-02-22
AU2009266125A1 (en) 2010-01-07
CN102083441A (zh) 2011-06-01
BRPI0913889B1 (pt) 2019-02-05
KR20110031357A (ko) 2011-03-25
ES2444581T3 (es) 2014-02-25
PL2310018T3 (pl) 2014-05-30
NI201100008A (es) 2011-08-10
CL2013000709A1 (es) 2013-08-23
NZ590276A (en) 2012-12-21
AU2009266125B2 (en) 2015-06-04
WO2010000399A1 (de) 2010-01-07
CL2010001577A1 (es) 2011-05-06
IL209698A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
IN2014DN06501A (es)
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
GEP20166438B (en) Imidazopyrrolidinone compounds
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
MX2011009847A (es) Agentes antihelminticos y su uso.
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
CR20110255A (es) Nuevos compuestos 578
MY148948A (en) Catecholamine derivatives and prodrugs thereof
CL2009000381A1 (es) Compuestos derivados de tiazol o tiazol-5-carboxamida, inhibidores de la actividad estearoil-coa-desaturasa humana (scd); composicion farmaceutica; y uso para el tratamiento de un trastorno o enfermedad mediada por las enzimas de scd, tal como diabetes, obesidad, enfermedad cardiovascular, lipidos elevados, entre otras.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
CO6321270A2 (es) Nuevas posibilidades de lucha contra la giardiasis
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias

Legal Events

Date Code Title Description
FG Application granted